Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01095562 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With Schizophrenia
A Phase 2 study, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 2
- Development phase
- 207
- Enrollment target
NCT01095562 is a Phase 2 study that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 207 participants.
The verdict
NCT01095562, a Phase 2 study, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 207 participants
- Enrollment target
Study Summary
This is an efficacy and safety study evaluating an experimental treatment for cognitive deficits in adults with schizophrenia.
Interventions
- DRUG Placebo
- DRUG ABT-126
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 207 participants |
| Start Date | 2010-03 |
| Est. Completion | 2011-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01095562
The ClinicalTrials.gov registry entry for NCT01095562 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 207 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01095562 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01095562 about?
NCT01095562 is a clinical study titled "Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With Schizophrenia". This is an efficacy and safety study evaluating an experimental treatment for cognitive deficits in adults with schizophrenia.
What is the current status of trial NCT01095562?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 207 participants. The study started on 2010-03. Estimated completion is 2011-09.
What interventions are being tested in trial NCT01095562?
The interventions under investigation include: Placebo (DRUG), ABT-126 (DRUG).
Who is sponsoring clinical trial NCT01095562?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.